NYSE:ZETA
NYSE:ZETASoftware

Zeta Global Holdings (NYSE:ZETA) Raises Revenue Guidance With Improved First Quarter Results

Zeta Global Holdings (NYSE:ZETA) has recently raised its revenue guidance for the second quarter and full year of 2025, reflecting positive growth expectations amidst an already improved first quarter earnings report. In the past week, the company's stock price experienced a 7.4% increase, coinciding with a surge in the broader market driven by strong job reports and optimism around potential trade talks between China and the U.S. While the broader market rose 1.8%, Zeta's enhanced financial...
NYSE:GDDY
NYSE:GDDYIT

GoDaddy (NYSE:GDDY) Updates Guidance after First Quarter Revenue Hits US$1,194 Million

GoDaddy (NYSE:GDDY) saw a 6.62% price increase last week, which aligns with broader market trends driven by positive economic indicators such as a strong jobs report and optimism from potential U.S.-China trade talks. The company's reaffirmation of its earnings guidance for 2025, despite the recent decline in net income and earnings per share, likely supported investor confidence. Meanwhile, the general market environment remained bullish with the S&P 500 on its longest winning streak since...
NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss of US$46 Million in Q1 2025

Viking Therapeutics (NasdaqCM:VKTX) has experienced a share price increase of 20% over the last month. This comes amidst the company's report of increased financial losses, with a net loss of $46 million in Q1 2025, up from $27 million the previous year, and a change in their auditing firm from Marcum to CBIZ. While these company-specific events likely added some pressure, broader market trends including a significant S&P 500 rally, driven by optimistic earnings reports and potential easing...
NasdaqGS:MRNA
NasdaqGS:MRNABiotechs

Moderna (NasdaqGS:MRNA) Reports Decrease in Q1 Revenue and Net Loss

Moderna (NasdaqGS:MRNA) recently reported a decline in revenue for Q1 2025, but managed to reduce its net loss and improve its loss per share. Despite this, the company's stock price was relatively flat over the last month. This performance aligns with broader market trends, which saw significant gains due to strong job reports and positive sentiment from potential U.S.-China trade talks. While Moderna's financial results may have added weight to broader market optimism, the stock's minimal...